69. The representative of Japan said that there was no conflict between the TRIPS Agreement and the CBD and that they should coexist in a mutually supportive manner. He said that the discussion on what should be disclosed in a patent application should be based on the requirements of the patent system per se. The disclosure issue should be discussed mainly at the IGC of the WIPO because of its expertise and because its Director-General had shown his strong support to that forum. His delegation shared many views with the United States, as stated in their paper as it proposed to make some impact on biopiracy without putting additional burden on to the patent system.
